NextRNA Therapeutics
PrivateLast Round
Series A
Mar 1, 2022
Total Funding Raised
$56.1M
Company Overview
NextRNA Therapeutics operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Series A round in March 2022.
NextRNA Therapeutics is a biotechnology company that developed small molecule therapeutics targeting dysregulated long non-coding RNAs (lncRNAs) to treat diseases in oncology and neuroscience.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NextRNA Therapeutics Comparables
Compare NextRNA Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Arrakis Therapeutics | 88% | |
| Amaroq Therapeutics | 86% | |
| Expansion Therapeutics | 84% |
For institutional investors. Book with your work email.
NextRNA Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 1, 2022 | ||||
| Seed | Mar 1, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
NextRNA Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Jefferies | Seed, Series A |
| Circle Squared Alternative Investments | Series A |
| Evans Capital | Seed, Series A |
| Rivas Capital | Seed, Series A |
| Willett Advisors | Seed, Series A |
| Cobro Ventures | Seed, Series A |
| LightChain Capital | Seed, Series A |
NextRNA Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about NextRNA Therapeutics's valuation, stock price, and market status.
Is NextRNA Therapeutics a public or private company?
NextRNA Therapeutics is a private company.
What is the current stock price of NextRNA Therapeutics?
NextRNA Therapeutics is a private company, so its shares have no public market price. Caplight tracks NextRNA Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is NextRNA Therapeutics worth (valuation)?
Valuation information for NextRNA Therapeutics is not publicly available.
Can I buy NextRNA Therapeutics stock?
NextRNA Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was NextRNA Therapeutics's last funding round?
NextRNA Therapeutics's most recent funding round was Series A on March 1, 2022.
Who are the main investors in NextRNA Therapeutics?
Key investors in NextRNA Therapeutics include Cobro Ventures, LightChain Capital.
Will NextRNA Therapeutics IPO soon?
No public IPO plans have been announced for NextRNA Therapeutics.
How can I track NextRNA Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in NextRNA Therapeutics's shares on secondary markets.